• All
• Altavant
• Enzyvant
• Myovant
• Spirovant
• Sumitovant
• Urovant

• 

  April 27, 2021ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia
• 

  April 26, 2021Altavant Sciences Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS
• 

  April 21, 2021Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting
• 

  April 15, 2021Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology
• 

  April 12, 2021Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
• 

  April 12, 2021Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
• 

  March 29, 2021Sumitovant Biopharma Completes Acquisition of Urovant Sciences
• 

  March 26, 2021Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
• 

  March 02, 2021Sumitovant Biopharma’s Portfolio of Innovative Companies Achieve Significant Clinical and Corporate Milestones in its Third Quarter of Operation
• 

  February 18, 2021Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID
• « Previous 1 … 3 4 5 6 7 … 21 Next »